Group 4G: Triple Negative Breast Cancer—Metastatic

Friday, June 10
10:00 am – 11:30 am Eastern Time (US/New York)

Mentor: Janice Cowden, R.N.

Janice was diagnosed with Stage IV metastatic triple-negative breast cancer in 2016, a recurrence from Stage I tnbc nearly 5 years prior. An exceptional responder to her first line of treatment, Janice is extremely fortunate to have had no evidence of disease (NED) since November 2016. With a 20+ year background in Nursing, science, research and studying diseases have always been of interest. Nine months following her MBC diagnosis, Janice launched into MBC Patient Advocacy by participating in training through Living Beyond Breast Cancer’s (LBBC) Hear My Voice Advocacy Outreach program in 2017. As a Research Advocate, Janice attends multiple scientific breast cancer conferences annually to learn more about MBC research and disease. She has a strong interest in partnering with Scientists, Researchers, and Clinicians to work towards more effective treatment modalities that enable MBC patients to live longer and provide a better quality of life. In 2019, she completed NBCC’s Project LEAD. Predominantly, Janice’s advocacy interests include MBC education, awareness, & research, legislative/policy, as well as Peer-to-Peer support. She is a trained Peer Support Volunteer Leader for METAvivor Research & Support and serves as a Peer mentor for LBBC’s volunteer Helpline, as well as for ABCD. Janice is involved in several patient-led advocacy groups, including GRASP, the Patient Centered Dosing Initiative (PCDI), ACE Collaborative Group, the Love Army Research Scientific Advisory Committee, and is the founder and Administrator of The Newly Diagnosed MBC Facebook Peer Support group. She considers herself a lifelong learner and enjoys educating others. In her spare time, Janice enjoys reading, swimming, and spending time with her family, including three grandchildren.

Twitter: @JaniceTNBCmets

Scientist: Philipp Aftimos, M.D.

Philippe Aftimos, M.D. is a medical oncologist and the Clinical Trials Development Leader at the Clinical Trials Conduct Unit of Institut Jules Bordet, a comprehensive cancer center in Brussels.

He works in the fields of breast cancer, new drug development and precision medicine. At Institut Jules Bordet, he heads the new drug development program at the Clinical Trials Conduct Unit. He has participated in the development of novel monoclonal antibodies and antibody-drug conjugates for the treatment of breast cancer as well as in the development of novel endocrine therapies. He currently leads multiple projects with agents targeting epigenetics. As a clinical research physician, he is a member of the think tank of the Oncodistinct network and is a member of the Scientific Executive Committee of the International Breast Cancer Study Group.

In the precision medicine field, Dr. Aftimos has participated in drafting the national Belgian NGS guidelines. He is co-PI of AURORA (Aiming to Understand the Molecular Aberrations of Metastatic Breast Cancer), a large European molecular screening program launched by the Breast International Group.  He is also co-PI of the Belgian Society of Medical Oncology precision medicine program, a national clinico-genomic data sharing program. He co-created and leads the Belgian national molecular tumor board.

Twitter: @aftimosp